Investigation Launched After Soleno's DCCR Issues Lead to Share Value Drop

Legal Trouble for Soleno Therapeutics Due to DCCR Launch

In a notable development for the pharmaceutical industry, Soleno Therapeutics, Inc. (NASDAQ: SLNO) has come under fire from investors following a significant downturn in its share price after the troubled launch of its drug DCCR, branded as VYKAT™ XR. A class action lawsuit has been initiated against the company, targeting investors who procured common stock between March 26 and November 4, 2025.

The lawsuit stems from a disappointing announcement made on November 5, 2025, regarding DCCR, a product aimed at treating hyperphagia—a condition characterized by an insatiable appetite often associated with Prader-Willi Syndrome (PWS), a rare genetic disorder. The revelation that the drug encountered major hurdles sparked an immediate 26% decline in Soleno's stock price on the same day.

Hagens Berman, a national law firm representing shareholder rights, is investigating whether Soleno misled investors concerning the safety and commercial viability of DCCR, especially after claims were made indicating that the launch was proceeding better than expected. The lawsuit alleges that the company misrepresented safety data related to the drug, leading investors to underestimate the risks associated with its use.

More alarming, according to the lawsuit, is the claim that Soleno's Phase 3 clinical trials may have concealed critical safety indicators concerning DCCR's administration, specifically issues like fluid retention in trial participants. This supposed misconduct has led to skepticism about the potential widespread adverse effects post-launch, which could severely affect the drug's market performance.

The atmosphere became even more charged following comments from activist short seller Scorpion Capital, which brought to light various concerns regarding the drug's efficacy and the integrity of the clinical trials. The firm observed a troubling trend of children requiring hospitalization for possible heart failure within a short span after using VYKAT™ XR. In light of these allegations, Scorpion posited that Soleno's data might not be as reliable as presented, highlighting red flags regarding the trial's methodology and outcomes.

Moreover, Soleno's management, during their Q3 2025 earnings call on November 4, acknowledged disturbances in their launch strategy, attributing these challenges partly to the fallout from the August short seller report. Since then, Soleno's stock has plummeted nearly 40%.

Reed Kathrein, the attorney leading the investigation for Hagens Berman, expressed serious concerns about the discrepancies between Soleno's public statements and the reality experienced by investors. The firm is calling on anyone who has suffered significant financial losses due to the downturn to come forward and share their experiences. They are also urging individuals who possess critical non-public information about the company to consider cooperating with the investigation, as whistleblowers can potentially benefit from significant rewards under SEC programs.

This situation serves as a crucial reminder of the complexities within the pharmaceutical industry and the significant risks inherent in the commercialization of new treatments. Soleno must now navigate through growing investor skepticism and potential legal ramifications while attempting to recover its market standing and credibility.

With the class-action lawsuit gaining traction, the future of Soleno Therapeutics and its product DCCR now hangs in the balance as investors and analysts alike watch closely to see how the firm manages this tumultuous chapter.